IP Library Granted Patent US 9,255,293
Granted Patent B2
US 9,255,293 · App. 13/879,572 · Granted Feb 9, 2016

Integrated capture and amplification of target nucleic acid for sequencing

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,255,293
App. No.
13/879,572
Granted
Feb 9, 2016
Kind
B2
Abstract

The invention provides efficient methods of preparing a target nucleic acid in a form suitable for sequencing. The methods are particularly amenable for preparing high quality nucleic acids for massively parallel sequencing. The methods involve capturing a target nucleic acid from a sample and PCR amplification of the target nucleic acid. The target nucleic acid is captured by binding to a capture probe, which in turn binds to an immobilized probe. The immobilized probe is typically immobilized via a magnetic bead. The captured target nucleic acid is PCR amplified by thermocycling without prior dissociation of the target nucleic acid from the beads. The efficiency of the method lies in part in that both the capture and amplification steps are performed in a single vessel. The amplified nucleic acid can then be sequenced.

Claims (32)

1. A method of preparing a target nucleic acid, comprising

contacting a target nucleic acid with a capture probe and an immobilized probe, the capture probe comprising a first segment that hybridizes to the target nucleic acid and a second segment that hybridizes to the immobilized probe, wherein the target nucleic acid hybridizes to the first segment of the capture probe, and the second segment of the capture probe hybridizes to the immobilized probe, thereby forming a capture hybrid capturing the target nucleic acid; and

performing a PCR amplification of the captured target nucleic acid without a step of dissociating the capture hybrid before initiating thermocycling in the PCR amplification; wherein the PCR amplification is performed in the same vessel as the contacting step and wherein the amplified target nucleic acid comprises at least one mutation that is present in less than 10% of molecules of the target nucleic acid.

2. The method of claim 1 , further comprising sequencing the amplified target nucleic acid.

3. The method of claim 1 , wherein the target nucleic acid is an RNA molecule and the PCR amplification is an RT-PCR amplification.

4. The method of claim 3 , wherein the target nucleic acid is a population of RNA molecules, and the RT-PCR amplification results in an amplified population of nucleic acids, which are sequenced in the sequencing step.

5. The method of claim 4 , wherein the target nucleic acid is a viral RNA population.

6. The method of claim 5 , wherein the viral mRNA population includes viral mRNA and/or viral genomic RNA wherein species of the viral RNA population differ from one another by mutations, which are identified by the sequencing step or wherein the identified mutations include at least one drug resistance mutation.

7. The method of claim 1 , wherein at least one identified mutation is present in less than 1% of molecules in the population of mRNA molecules.

8. The method of claim 7 , wherein the viral RNA population is an HIV, HCV or HBV mRNA population from a patient sample.

9. The method of claim 1 , wherein the immobilized probe is immobilized via attachment to a magnetic bead.

10. The method of claim 9 , wherein the concentration of immobilized probe linked to magnetic beads is 10-30 pg/ml.

11. The method of claim 1 , wherein the PCR involves thermocycling between temperature ranges of 90-99° C. and 55-65° C., or 95° C. and 55-65° C.; or wherein the concentration of the capture probe is 0.2-0.8 pmol/ml.

12. The method of claim 1 , wherein the sequencing step sequences at least 75% of the length of the target nucleic acid or wherein the RT-PCR is performed with a pair of primers hybridizing to conserved regions of the target molecule or its complement and proximate to the ends of the target molecule so as to allow amplification of at least 75% of the target molecule.

13. The method of claim 2 , wherein at least 100,000 molecules in the population of the target molecules are sequenced.

14. The method of claim 1 , wherein the target nucleic acid is present in a serum or plasma sample.

15. The method of claim 14 , wherein the serum or plasma sample is treated with detergent to release viral RNA.

16. The method of claim 1 , wherein the first segment includes a nucleic acid of 10-30 bases complementary to the target nucleic acid.

17. The method of claim 1 , wherein the first segment is complementary to a conserved region of a viral RNA target.

18. The method of claim 5 , wherein the contacting is performed with a plurality of capture probes, the capture probes having the same second segment and different first segments, the different first segments being complementary to different conserved regions of a viral RNA target.

19. The method of claim 1 , wherein the first segment includes a random sequence of nucleotides that hybridizes nonspecifically to the target nucleic acid.

20. The method of claim 1 , wherein the second segment includes a nucleic acid of 10-30 bases complementary to a nucleic acid of 10-30 contiguous bases in the immobilized probe.

21. The method of claim 20 , wherein the nucleic acid of the second segment is a homopolymer and the nucleic acid of the immobilized probe constitute a complementary homopolymer.

22. The method of claim 21 , wherein the homopolymer of the second segment is poly-A and the homopolymer of the immobilized probe is poly-T or vice versa.

23. The method of claim 1 , wherein the second segment of the capture probe and the complementary segment of the immobilized probe are L-nucleic acids.

24. The method of claim 1 , wherein the target nucleic acid is contacted with the capture probe and immobilized probe simultaneously.

25. The method of claim 1 , wherein the target nucleic acid is contacted with the capture probe before the immobilized probe.

26. The method of claim 1 , wherein the binding of the target nucleic acid to the capture probe occurs under first hybridization conditions and the binding of the capture probe to the immobilized probe occurs under second hybridization conditions and the first conditions are more stringent than the second conditions.

27. The method of claim 26 , wherein the first conditions are at a higher temperature than the second conditions.

28. The method of claim 26 , wherein the first conditions include a temperature of 50-70° C. and the second conditions include room temperature.

29. The method of claim 2 , wherein the sequencing is performed by single-molecule real-time sequencing.

30. The method of claim 1 , further comprising forming a circular template comprising the amplified target nucleic acid wherein the sequencing generates a sequencing read containing multiple copies of the target nucleic acid.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Apr 28, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC., ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO DIRECT RADIOGRAPHY CORP.; CYTYC CORPORATION, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO BIOLUCENT, LLC; CYTYC SURGICAL PRODUCTS, LLC, AS SUCCESSOR-BY-CONVERSION TO CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; GEN-PROBE INCORPORATED, ON ITS OWN BEHALF AND AS SUCCESSOR-BY-MERGER TO THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.
Reel/Frame 075566/0039 →
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
SECURITY AGREEMENT Recorded Aug 7, 2015
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 036307/0199 →
SECURITY INTEREST RELEASE R/F 030755 0031 Recorded Jul 17, 2015
From: GOLDMAN SACHS BANK USA, AS COLLATERAL AGENT
To: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRAPHY CORP.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE INCORPORATED
Reel/Frame 036127/0538 →
SECURITY AGREEMENT Recorded Jul 9, 2013
From: HOLOGIC, INC.; BIOLUCENT, LLC; CYTYC CORPORATION; CYTYC SURGICAL PRODUCTS, LIMITED PARTNERSHIP; DIRECT RADIOGRPHY CORP.; SUROS SURGICAL SYSTEMS, INC.; THIRD WAVE TECHNOLOGIES, INC.; GEN-PROBE, INCORPORATED
To: GOLDMAN SACHS BANK USA
Reel/Frame 030755/0031 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 8, 2013
From: POLLNER, REINHOLD; LEE, SHYUN-SHYUN
To: GEN-PROBE INCORPORATED
Reel/Frame 030374/0815 →